EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective
| Autor: | Taminato, A, Barbosa, A, Magro, FJB, Federico, P, Prioli, RNT, Goldflus, S, Migliavaca, CB, Falavigna, M |
|---|---|
| Zdroj: | In Value in Health December 2022 25(12) Supplement:S54-S54 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect